MedTrace Logo

Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue

NCT01044004 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2013-07-23

No results posted yet for this study

Summary

To determine whether armodafinil is more effective than placebo in reducing fatigue.

Conditions

Interventions

DRUG

Armodafinil

Armodafinil 150 mg/day for 13 weeks

DRUG

placebo

Placebo 150mg/day for 13 weeks

DRUG

Armodafinil

Armodafinil 150 mg/day for 13 weeks

DRUG

placebo

Placebo 150mg/day for 13 weeks

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Nina Wagner-Johnston, M · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2012-06-30
Completion
2012-06-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01044004 on ClinicalTrials.gov